News & Updates

Show Multimedia Only

Vemircopan for generalized myasthenia gravis misses mark in phase 2 study

The oral, selective factor D inhibitor vemircopan has shown no evidence of benefit in the treatment of adult patients with acetylcholine receptor antibody-positive (AChR-Ab+) generalized myasthenia gravis in a phase 2 trial.

Vemircopan for generalized myasthenia gravis misses mark in phase 2 study

2 hours ago

Is spironolactone combined with low-dose minoxidil safe for hair loss in women?

3 hours ago

Combination therapy with oral spironolactone and low-dose oral minoxidil appears safe and tolerable among adult females with hair loss, reports a study. However, those using one or more blood pressure (BP)-altering medications are at increased risk of hypotension-related symptoms.

Is spironolactone combined with low-dose minoxidil safe for hair loss in women?

3 hours ago

Orforglipron superior to dapagliflozin in metformin-resistant T2D

4 hours ago by

A recent study comparing dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, with orforglipron, an oral nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist (RA), has found superior glycaemic control and weight loss with the latter.

Orforglipron superior to dapagliflozin in metformin-resistant T2D

4 hours ago

Mazdutide cuts weight in adults with obesity, T2D

5 hours ago by

The use of mazdutide among adults with obesity results in a clinically significant weight reduction and improvements in cardiometabolic risk factors, with an acceptable safety profile, as shown in the phase 3 GLORY-2 trial presented at ADA 2026.

Mazdutide cuts weight in adults with obesity, T2D

5 hours ago

MAESTRO-NASH updates validate extrahepatic safety of resmetirom

6 hours ago by

In a post hoc analysis of the phase III MAESTRO-NASH trial presented at ADA 2026, systemic thyroid function remained stable with resmetirom, supporting its extrahepatic safety in individuals with metabolic dysfunction-associated steatohepatitis (MASH).

MAESTRO-NASH updates validate extrahepatic safety of resmetirom

6 hours ago

Novel dual PDE3/PDE4 inhibitor shows promise in COPD

10 hours ago

In the treatment of patients with chronic obstructive pulmonary disease (COPD), the investigational dual phosphodiesterase (PDE) 3 and 4 inhibitor TQC3721 helps improve lung function, according to a phase 2 PACER-II study.

Novel dual PDE3/PDE4 inhibitor shows promise in COPD

10 hours ago

Satralizumab cuts relapse risk in MOGAD

13 hours ago by

Satralizumab reduces the risk of relapse by 68 percent in adults and adolescents with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), as shown in the phase III METEOROID study presented at AAN 2026.

Satralizumab cuts relapse risk in MOGAD

13 hours ago

Fluvoxamine wins, metformin disappoints in long COVID fatigue

14 hours ago by

The antidepressant fluvoxamine reduces long COVID fatigue, whereas the antidiabetic agent metformin fails to outperform placebo in the randomized REVIVE-TOGETHER trial.

Fluvoxamine wins, metformin disappoints in long COVID fatigue

14 hours ago

Triple hormone receptor agonist delivers glucose-lowering, weight loss benefits in T2D

a day ago by

For individuals with type 2 diabetes (T2D) that is inadequately controlled by diet and exercise alone, once-weekly administration of the triple hormone receptor agonist retatrutide helps improve glycaemic control, and this benefit is accompanied by substantial weight reduction, as shown in the phase III TRANSCEND-T2D-1 study.

Triple hormone receptor agonist delivers glucose-lowering, weight loss benefits in T2D

a day ago

Switching between JAK inhibitors a feasible solution for severe alopecia areata

a day ago

Patients with treatment-refractory alopecia areata (AA) may benefit from switching between Janus kinase inhibitors (JAKis), suggests a study.

Switching between JAK inhibitors a feasible solution for severe alopecia areata

a day ago

News & Updates

Showing Pharmacy articles

Showing

Specialty:

Vemircopan for generalized myasthenia gravis misses mark in phase 2 study

Vemircopan for generalized myasthenia gravis misses mark in phase 2 study

Is spironolactone combined with low-dose minoxidil safe for hair loss in women?

Is spironolactone combined with low-dose minoxidil safe for hair loss in women?

Orforglipron superior to dapagliflozin in metformin-resistant T2D

Orforglipron superior to dapagliflozin in metformin-resistant T2D

Mazdutide cuts weight in adults with obesity, T2D

Mazdutide cuts weight in adults with obesity, T2D

MAESTRO-NASH updates validate extrahepatic safety of resmetirom

MAESTRO-NASH updates validate extrahepatic safety of resmetirom

Novel dual PDE3/PDE4 inhibitor shows promise in COPD

Novel dual PDE3/PDE4 inhibitor shows promise in COPD

Satralizumab cuts relapse risk in MOGAD

Satralizumab cuts relapse risk in MOGAD

Fluvoxamine wins, metformin disappoints in long COVID fatigue

Fluvoxamine wins, metformin disappoints in long COVID fatigue

Triple hormone receptor agonist delivers glucose-lowering, weight loss benefits in T2D

Triple hormone receptor agonist delivers glucose-lowering, weight loss benefits in T2D

Switching between JAK inhibitors a feasible solution for severe alopecia areata

Switching between JAK inhibitors a feasible solution for severe alopecia areata